DE60141969D1 - Verwendung eines replikationdefizienten pockenvirusvektors zur erhöhung der cd4+ t-zell-immunantwort gegen antigen - Google Patents

Verwendung eines replikationdefizienten pockenvirusvektors zur erhöhung der cd4+ t-zell-immunantwort gegen antigen

Info

Publication number
DE60141969D1
DE60141969D1 DE60141969T DE60141969T DE60141969D1 DE 60141969 D1 DE60141969 D1 DE 60141969D1 DE 60141969 T DE60141969 T DE 60141969T DE 60141969 T DE60141969 T DE 60141969T DE 60141969 D1 DE60141969 D1 DE 60141969D1
Authority
DE
Germany
Prior art keywords
replication
response against
deficient
pocket
increase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60141969T
Other languages
English (en)
Inventor
Adrian V S Hill
Helen Mcshane
Sarah Gilbert
William Reece
Joerg Schneider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Biomedica UK Ltd
Original Assignee
Oxxon Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxxon Therapeutics Ltd filed Critical Oxxon Therapeutics Ltd
Application granted granted Critical
Publication of DE60141969D1 publication Critical patent/DE60141969D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DE60141969T 2000-09-21 2001-09-13 Verwendung eines replikationdefizienten pockenvirusvektors zur erhöhung der cd4+ t-zell-immunantwort gegen antigen Expired - Lifetime DE60141969D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0023203.3A GB0023203D0 (en) 2000-09-21 2000-09-21 Vaccination method
PCT/GB2001/004116 WO2002024224A2 (en) 2000-09-21 2001-09-13 Use of replication-deficient poxvirus vector to boost cd4+ t cell immune response to antigen

Publications (1)

Publication Number Publication Date
DE60141969D1 true DE60141969D1 (de) 2010-06-10

Family

ID=9899889

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60141969T Expired - Lifetime DE60141969D1 (de) 2000-09-21 2001-09-13 Verwendung eines replikationdefizienten pockenvirusvektors zur erhöhung der cd4+ t-zell-immunantwort gegen antigen

Country Status (10)

Country Link
US (1) US20040018177A1 (de)
EP (1) EP1320379B8 (de)
JP (1) JP5102930B2 (de)
AT (1) ATE465750T1 (de)
AU (2) AU2001286109B2 (de)
CA (1) CA2422094C (de)
DE (1) DE60141969D1 (de)
ES (1) ES2345604T3 (de)
GB (2) GB0023203D0 (de)
WO (1) WO2002024224A2 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
US20030138454A1 (en) * 1997-06-09 2003-07-24 Oxxon Pharmaccines, Ltd. Vaccination method
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
CZ295808B6 (cs) 2000-11-23 2005-11-16 Bavarian Nordic A/S Modifikovaný virus vakcinie typu Ankara
US7628980B2 (en) 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
GB0118532D0 (en) * 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
CA2467486A1 (en) * 2001-11-30 2003-06-12 Isis Innovation Limited Vaccine
IL163701A0 (en) 2002-04-19 2005-12-18 Bavarian Nordic As Modified vaccinia virus ankara for the vaccinationof neonates
CA2494359A1 (en) * 2002-05-20 2003-11-27 Japan Science And Technology Agency Bcg vaccine and utilization thereof
EA009008B1 (ru) 2002-09-05 2007-10-26 Бавариан Нордик А/С Способ амплификации вируса оспы
DE10249390A1 (de) * 2002-10-23 2004-05-13 Ruprecht-Karls-Universität Heidelberg Rekombinante MVA-Stämme als potentielle Impfstoffe gegen P.falciparum-Malaria
US20050175627A1 (en) * 2003-09-24 2005-08-11 Oxxon Therapeutics Ltd. HIV pharmaccines
GB2421025A (en) * 2004-12-09 2006-06-14 Oxxon Therapeutics Ltd HSV vaccination vectors
WO2006120474A2 (en) * 2005-05-13 2006-11-16 Oxxon Therapeutics Ltd Compositions for inducing an immune response against tumor antigens
CA2678404C (en) * 2007-02-28 2019-03-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
SI3188753T1 (sl) 2014-09-03 2020-07-31 Bavarian Nordic A/S Metode in sestave za induciranje zaščitne imunosti proti okužbi s filovirusom
CN107106673A (zh) 2014-09-03 2017-08-29 巴法里安诺迪克有限公司 用于增强免疫应答的方法和组合物
SG11201702110RA (en) 2014-09-26 2017-04-27 Beth Israel Deaconess Medical Ct Inc Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
CN105753989A (zh) * 2014-12-15 2016-07-13 牛津疫苗医学生物科技（英国）有限公司 人工多抗原融合蛋白及其制备和应用
PL3407910T3 (pl) 2016-01-29 2022-08-16 Bavarian Nordic A/S Rekombinowana zmodyfikowana szczepionka przeciwko wirusowi krowianki ankara (mva) przeciwko wirusowi zapalenia mózgu koni
AU2017249424B2 (en) 2016-04-13 2023-08-24 Janssen Pharmaceuticals, Inc. Recombinant arterivirus replicon systems and uses thereof
EP3484507A1 (de) 2016-07-15 2019-05-22 Janssen Vaccines & Prevention B.V. Verfahren und zusammensetzungen zur induzierung von schützender immunität gegen eine marburg-virus-infektion
JP2019526580A (ja) 2016-09-02 2019-09-19 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 抗レトロウイルス処置を受けている対象においてヒト免疫不全ウイルス感染に対する免疫応答を誘発するための方法
BR112019007433A2 (pt) 2016-10-17 2019-07-02 Synthetic Genomics Inc sistemas de replicon de vírus recombinante e usos dos mesmos
US11845939B2 (en) 2016-12-05 2023-12-19 Janssen Pharmaceuticals, Inc. Compositions and methods for enhancing gene expression
EP3606553A1 (de) 2017-04-06 2020-02-12 Janssen Vaccines & Prevention B.V. Mva-bn- und ad26.zebov- oder ad26.filo-prime-boost-schema
WO2019018724A1 (en) 2017-07-21 2019-01-24 Janssen Vaccines & Prevention B.V. METHODS FOR SAFE INDUCTION OF MULTICLADED CROSS-IMMUNITY AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN HUMAN BEINGS
WO2019055888A1 (en) 2017-09-18 2019-03-21 Janssen Vaccines & Prevention B.V. METHODS OF INDUCING AN IMMUNE RESPONSE AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN SUBJECTS UNDER ANTIRETROVIRAL TREATMENT
US11021692B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
SG11202005710YA (en) 2017-12-19 2020-07-29 Janssen Sciences Ireland Unlimited Co Methods and compositions for inducing an immune response against hepatitis b virus (hbv)
US11389531B2 (en) 2017-12-19 2022-07-19 Janssen Sciences Ireland Unlimited Company Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines
US11020476B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV)
JP2021511318A (ja) 2018-01-19 2021-05-06 ヤンセン ファーマシューティカルズ，インコーポレーテッド 組換えレプリコン系を使用する免疫応答の誘導および増強
TW202110476A (zh) 2019-05-22 2021-03-16 荷蘭商傑森疫苗防護公司 於接受抗反轉錄病毒治療之個體中誘發抗人類免疫缺乏病毒感染之免疫反應的方法
WO2021260065A1 (en) 2020-06-24 2021-12-30 Consejo Superior De Investigaciones Científicas (Csic) Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
EP3928789A1 (de) 2020-06-24 2021-12-29 Consejo Superior de Investigaciones Científicas (CSIC) Mva-basierter impfstoff gegen covid-19 exprimierende sars-cov-2-antigene
AU2021303478A1 (en) 2020-07-08 2023-02-16 Janssen Sciences Ireland Unlimited Company RNA replicon vaccines against HBV
WO2022269003A1 (en) 2021-06-23 2022-12-29 Consejo Superior De Investigaciones Cientificas MVA-BASED VACCINE EXPRESSING A PREFUSION-STABILIZED SARS-CoV-2 S PROTEIN
EP4108257A1 (de) 2021-06-23 2022-12-28 Consejo Superior De Investigaciones Científicas Impfstoff auf mva-basis gegen covid-19, der ein präfusionsstabilisiertes sars-cov-2-s-protein exprimiert
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses
EP4316514A1 (de) 2022-08-03 2024-02-07 Consejo Superior de Investigaciones Científicas (CSIC) Vektoren auf mva-basis und ihre verwendung als impfstoff gegen sars-cov-2
WO2024064931A1 (en) * 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of liver stage antigens and related methods
WO2024063788A1 (en) * 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of malaria antigens and related methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
JP2003531865A (ja) * 2000-04-28 2003-10-28 アメリカ合衆国 Ｄｎａおよびワクシニアウイルスベクターワクチンの組み合わせを用いた免疫原性の改善
AU2001258102B2 (en) * 2000-05-10 2007-03-01 Aventis Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof

Also Published As

Publication number Publication date
WO2002024224A2 (en) 2002-03-28
EP1320379A2 (de) 2003-06-25
GB2384709B (en) 2005-05-04
EP1320379B8 (de) 2010-06-02
CA2422094C (en) 2011-04-19
JP5102930B2 (ja) 2012-12-19
US20040018177A1 (en) 2004-01-29
GB0023203D0 (en) 2000-11-01
AU8610901A (en) 2002-04-02
WO2002024224A3 (en) 2002-06-13
JP2004509149A (ja) 2004-03-25
GB2384709A (en) 2003-08-06
ATE465750T1 (de) 2010-05-15
AU2001286109B2 (en) 2006-12-14
ES2345604T3 (es) 2010-09-28
GB0308955D0 (en) 2003-05-28
CA2422094A1 (en) 2002-03-28
EP1320379B1 (de) 2010-04-28

Similar Documents

Publication Publication Date Title
DE60141969D1 (de) Verwendung eines replikationdefizienten pockenvirusvektors zur erhöhung der cd4+ t-zell-immunantwort gegen antigen
CY1105594T1 (el) Παραλλαγη τροποποιημενου ιου vaccinia ankara
DE69943170D1 (de) Immunologische Zusammensetzung und Impfstoffe, die einen auf N-Formyl-Methionyl Peptide bestehenden Adjuvans enthalten
DK1326636T3 (da) Vaccinesammensætning
EA200801798A1 (ru) Виросомоподобные везикулы, содержащие антигены, производные от gp41
ATE328068T1 (de) Papillomavirus vakzine
ATE333500T1 (de) Virus des porzinen reproduktiven und respiratorischen syndroms und dessen verwendung
DK0669133T3 (da) Multipotente paramunitetsindicerede midler baseret på kombinationer af koppeviruskomponenter, fremgangsmådde til fremstilling deraf og deres anvendelse som lægemidler
HK1076835A1 (en) Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter
DK1425404T3 (da) Vaccinia-MVA-E3L-mutanter og anvendelse deraf
WO2003076591A8 (en) Compositions and methods for generating an immune response
DE60020136D1 (de) Verwendung eines replikationdefizienten adenoviralenvektors zur herstellung eines medikaments zur erhöhung der cd8+ t-zell-immunantwort gegen antigen
MXPA05005549A (es) Virus recombinante de viruela que comprende al menos dos promotores ati de viruela de vaca.
MX2007002659A (es) Composicion vacunal contra el virus de la hepatitis c.
DK0964697T3 (da) Terapeutiske anvendelser af antigener eller epitoper knyttet til forringet cellulær peptidprocessering, f.eks. eksprimeret på RMA-S-celler transficeret med et B7-1-gen
BRPI0414073A (pt) método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo
ATE471990T1 (de) Transkutane immunisierung gegen papillomavirus mit virusähnlichen papillomaviruspartikeln
TW200509964A (en) VP1 of foot-and-mouth disease virus
ATE324450T1 (de) Polypeptid, das neutralisierende antikörper gegen hiv induziert
ATE310807T1 (de) Trennung eines humanen retrovirus
DK0858345T3 (da) Anvendelse af muteiner af vildtypecytokiner som immunogener
ATE145335T1 (de) Kreuzreaktive immunisierung gegen influenza
FR2856598A1 (fr) Peptides derives de la proteine mmp-2 et leur utilisation en immunotherapie antitumorale

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: OXFORD BIOMEDICA (UK) LTD., OXFORD, GB

8364 No opposition during term of opposition